Gene Editing: Fears Lead To Call For Moratorium At CBD, Discussions Ongoing 23/11/2018 by Catherine Saez, Intellectual Property Watch 2 Comments Gene editing techniques have opened the way to a new world of innovations. One of them is the potential eradication of malaria-carrying mosquitoes. What appears as a very attractive way to help with malaria eradication is denounced by civil society groups arguing that the technology is in its infancy. Wiping out entire species could have unforeseen environmental, health, and social consequences, they say. They are calling for a moratorium preventing the release of gene drive organisms in the wild. They also describe the gene drive mosquitoes as a Trojan horse, hiding broader interests of agricultural multinational corporations.
UN Committee Adopts ‘Landmark’ Declaration Reinforcing Peasants’ Rights To Seeds 23/11/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The social, humanitarian and cultural committee of the United Nations meeting this month adopted a UN Declaration on the Rights of Peasants and Other People Working in Rural Areas. The declaration includes the right to save, exchange, and sell farm-saved seeds, a contentious issue for which small farmers have been campaigning for years.
Convention On Biological Diversity Biennial Meeting Looks At How New Technologies Will Affect Its Objectives 20/11/2018 by Catherine Saez, Intellectual Property Watch 2 Comments Member countries of the UN Convention on Biological Diversity are meeting in Egypt for its biennial conference of the parties, and the conference of the parties of its protocol on access and benefit sharing, until the end of November. New technologies are high on the agenda of the meeting, such as synthetic biology and genetic sequence information of genetic resources, and how they will impact the convention’s objectives. Delegates are also expected to discuss a potential global multilateral benefit-sharing mechanism, and criteria for international specialised instruments of access and benefit-sharing which could substitute the protocol’s obligations in certain cases.
The Bumpy Road To Selection Patents In India 19/11/2018 by Intellectual Property Watch 1 Comment Namrata Chadha, of K&S Partners, a Tier 1 Indian law firm, discusses various crucial aspects relating to patenting of selection inventions in India, especially in pharmaceuticals and chemicals. Summary: The patenting of selection inventions is not plain sailing in India. The patentability of such inventions must be determined in accordance with the general provisions of the Indian Patents Act, as there is no separate provision for the same in the Act. Of the said general provisions, the assessment of inventive step and testing under section 3(d) of the Indian Patents Act can be perceived as the most critical to patentability of selected novel species. Additionally, the concepts of ‘implicit disclosure’ and the contrasting views on ‘coverage vs disclosure’ frequently makes it challenging for applicants to defend their novel selection under the Indian scenario. Given the lack of enough precedents in India on this aspect, to date the fate of selection patents depends mostly on the judgement of the patent controllers. Not all hope is lost, however, since not only the Indian Patent Office, but also the IPAB and higher Courts have time-and-again acknowledged the existence of selection patents in India.
Global Biotech Industry Revisits Geneva, Seeks To Build Relationships To Help Shape Policies 14/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment A global association representing biotechnology industries last week made a second annual visit to Geneva’s institutions to raise awareness of how the industry works, its needs, and how the association could participate better in policymaking. Dismissing fears of industry unduly influencing public policies, two representatives of the association sat down with Intellectual Property Watch’s Catherine Saez to explain the importance of biotechnology in solving the problems of the world, and the need to raise awareness of the perspective of the biotechnology sector.
WTO TRIPS Council Debates Competition Law, Plain Packaging’s Spread To Other Products 12/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Trade Organization intellectual property committee met last week with lively discussions on the benefit of IP rights protection for new businesses, and on the role of competition law to prevent abuses of those rights and in particular ensure greater access to medicines. Also, considering the recent WTO Dispute Settlement Body ruling on the tobacco plain packaging, some countries warned against this decision becoming a precedent and spreading to other goods, and undermining trademark protection.
Experts Assess Coming Changes In US Courts And Patentability 09/11/2018 by William New, Intellectual Property Watch 2 Comments NEW YORK — A panel of legal and government experts this week discussed trends in courts in the United States on patent cases and changes underway at the US Patent and Trademark Office. One conclusion? There may be a real shift in what is seen as patentable in the US, but it may take an act of Congress. [Note: part 1 of 2. The second part will address this week’s changes in the US Congress.]
El mecanismo mundial multilateral de participación en los beneficios: ¿Dónde será el Bretton Woods del Siglo XXI? 05/11/2018 by Intellectual Property Watch 3 Comments Bretton Woods es el nombre de un lugar y también de un sistema. El lugar, Bretton Woods, cuenta con el Hotel Mount Washington y vistas majestuosas de las Montañas Blancas de New Hampshire. El sistema Bretton Woods es el conjunto de normas financieras elaboradas durante una conferencia en dicho hotel que se realizó en julio de 1944 [1]. El sistema creó un orden monetario y permitió la recuperación económica en los años de la posguerra. Para los economistas, Bretton Woods representa al sistema. El éxito del mismo demuestra cómo el pensamiento económico puede penetrar la esfera política y realizar un cambio duradero. John Maynard Keynes, el Darwin de la Economía, encabezó la delegación británica.
No se trata solo de lo material: “El camino a seguir” para el CDB de la ONU, el PN y Half-Earth (mitad de la Tierra) 05/11/2018 by Intellectual Property Watch 1 Comment ¿Es la información “algo” o es “sobre algo”? Esa es esencialmente la pregunta ante la Decimocuarta Conferencia de las Partes (COP) del Convenio de las Naciones Unidas sobre la Diversidad Biológica de 1992 (CBD) que se reunirá del 19 hasta el 27 de noviembre del 2018. La pregunta es de 64 mil millones de dólares. La respuesta podría determinar la modalidad para el “acceso a recursos genéticos“ y una “distribución justa y equitativa de los beneficios” (ABS, por sus siglas en inglés), que es el tercer objetivo plasmado en el CDB. De ser la información transmitida en la vida “algo“ en sí y no “sobre algo”, los beneficios podrían ser mayores por órdenes de magnitud. Dicho de otro modo, los usuarios de recursos genéticos ¿están accediendo a información? o ¿están accediendo a materia, cuyas propiedades están esparcidas entre organismos y jurisdicciones? Si la la respuesta es “información”, se justifica un pago anual de decenas de miles de millones de dólares. En cambio, si la respuesta es “propiedades” justifica las “migajas“que se pagan actualmente.
US Interference In EU SPC Manufacturing Waiver “Unacceptable,” Says EU Generic Industry Group 24/10/2018 by Intellectual Property Watch Leave a Comment Generics industry group Medicines for Europe has declared United States interference in the European Union legislative process on the supplementary protection certificate (SPC) manufacturing waiver “unacceptable,” and an attempt to “influence the outcome of this EU legislative proposal.”
